[Aortic valve replacement with a Cryolife O'Brien stentless bioprosthesis]

Rev Esp Cardiol. 2007 Jan;60(1):45-50.
[Article in Spanish]

Abstract

Introduction and objectives: The Cryolife O'Brien xenograft is a stentless bioprosthesis constructed from noncoronary leaflets from three porcine aortic valves. The aim of this study was to investigate short-term results after aortic valve replacement with this composite xenograft.

Methods: Since October 1993, Cryolife O'Brien bioprostheses have been implanted in 210 patients. The patients' mean age was 70.9 (7.5) years (range 23-83 years). The indication was aortic stenosis in 132 cases, aortic insufficiency in 25 cases, and both lesions in 53 cases. Valve function was studied by echocardiography preoperatively, at discharge, and 6 and 12 months postoperatively.

Results: The 30-day mortality rate was 5.2% (11/210). Over time, the mean gradients decreased and the effective area index increased. In addition, the left ventricular mass index, wall thickness, and septum thickness also decreased shortly after surgery.

Conclusions: Use of the Cryolife O'Brien stentless bioprosthesis demonstrated satisfactory results at 1-year follow-up. Additional follow-up is required to assess the performance of this bioprosthesis over the long term.

Publication types

  • Evaluation Study

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Aortic Valve Insufficiency / mortality
  • Aortic Valve Insufficiency / surgery*
  • Aortic Valve Stenosis / mortality
  • Aortic Valve Stenosis / surgery*
  • Bioprosthesis*
  • Cause of Death
  • Female
  • Heart Valve Prosthesis Implantation* / adverse effects
  • Heart Valve Prosthesis Implantation* / mortality
  • Heart Valve Prosthesis*
  • Hospital Mortality
  • Humans
  • Logistic Models
  • Male
  • Middle Aged
  • Prosthesis Design
  • Survival Rate